| Literature DB >> 35571735 |
Shilpa Borehalli Mayegowda1, Manjula Ng1, Saad Alghamdi2, Banan Atwah2, Zain Alhindi2, Fahadul Islam3.
Abstract
Population of the world run into several health-related emergencies among mankind and humans as it creates a challenge for the evolution of novel drug discoveries. One such can be the emergence of multidrug-resistant (MDR) strains in both hospital and community settings, which have been due to an inappropriate use and inadequate control of antibiotics that has led to the foremost human health concerns with a high impact on the global economy. So far, there has been application of two strategies for the development of anti-infective agents either by classical antibiotics that have been derived for their synthetic analogs with increased efficacy or screening natural compounds along with the synthetic compound libraries for the antimicrobial activities. However, need for newer treatment options for infectious diseases has led research to develop new generation of antimicrobial activity to further lessen the spread of antibiotic resistance. Currently, the principles aim to find novel mode of actions or products to target the specific sites and virulence factors in pathogens by a series of better understanding of physiology and molecular aspects of the microbial resistance, mechanism of infection process, and gene-pathogenicity relationship. The design various novel strategies tends to provide us a path for the development of various antimicrobial therapies that intends to have a broader and wider antimicrobial spectrum that helps to combat MDR strains worldwide. The development of antimicrobial peptides, metabolites derived from plants, microbes, phage-based antimicrobial agents, use of metal nanoparticles, and role of CRISPR have led to an exceptional strategies in designing and developing the next-generation antimicrobials. These novel strategies might help to combat the seriousness of the infection rates and control the health crisis system.Entities:
Year: 2022 PMID: 35571735 PMCID: PMC9098294 DOI: 10.1155/2022/2500613
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
Figure 1Diagrammatic representation of different target sites for the antimicrobial agent's activity on a bacterial cell. ❶ Alteration in PBP: modified PBP is responsible for the mechanism of action of resistance seen in Gram-positive bacteria as it produces β-lactamases. For example, reduction in affinity of β-lactam antibiotics is due to the mutation on penicillin-binding protein. ❷ Efflux pumps: antibiotics are exported via the membrane proteins inside the cell and maintain their low-intracellular concentrations by pumping them out before they reach their target. Several unrelated antibiotics such as macrolides, tetracyclines, and fluoroquinolones (FQ) are been pumped by cytoplasmic membrane-associated multidrug transporters contributing in the development of MDR strains. ❸ Inhibitors of DNA replication: inhibition of the bacterial division by preventing enzyme DNA gyrase activity (nicks double-stranded DNA and negative supercoils and reseals) is facilitated by quinolones like FQ. ❹ Altered cell wall precursors: Gram-positive bacteria can be inhibited by glycopeptides like vancomycin or teicoplanin as they are involved suppression cell wall synthesis. ❺ DNA mutated-DNA gyrase and topoisomerase IV: quinolone mechanism of resistance involves modification of two enzymes: DNA gyrase and topoisomerase IV. Replication failure is due to mutations in genes gyrA and parC making FQ unable to bind. ❻ Folic acid metabolism inhibitors: combination of few drugs like sulphonamides and trimethoprim acts on biosynthetic pathway, which shows synergy and a reduced mutation rate for resistance. ❼ Alteration in the 30S subunit or 50S subunit: resistance to drugs that affect protein synthesis, that is, macrolides, tetracycline, and chloramphenicol, bind to 30S ribosomal subunit, whereas chloramphenicol, macrolides, lincosamides, and streptogramin B bind to 50S ribosomal subunit to suppress protein synthesis. ❽ Inhibitors of protein synthesis: tetracyclines offer resistance by inhibiting integrity of ribosomal structure and RNA polymerase mutations conferring resistance to rifampicin. ❾ Antibiotic inactivation by enzymes: β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferases are the three main enzymes that inactivate antibiotics. ❿ Porins: present in the outer membrane. The changed selectivity or decreased in porins stops the antimicrobials to act on the pathogens conferring resistance.
List of various plant compounds used for their antimicrobial properties [37].
| Scientific name | Common name | Compound | Antimicrobial activity |
|---|---|---|---|
| Berberis vulgaris | Barberry | Berberine | Bacteria and protozoa |
| Piper nigrum | Black pepper | Piperine |
|
| Rhamnus purshiana | Cascara sagrada | Tannins | Bacteria, fungi, and viruses |
| Matricaria chamomilla | Chamomile | Anthemic acid |
|
| Syzygium aromaticum | Clove | Eugenol | Bacteria, fungi, and Trypanosoma cruzi |
| Vaccinium spp. | Cranberry | Fructose | Bacteria |
| Eucalyptus globulus | Eucalyptus | Tannin | Bacteria and viruses |
| Allium sativum | Garlic | Allicin and ajoene | General |
| Hydrastis canadensis | Goldenseal | Berberine and hydrastine | Bacteria, |
| Camellia sinensis | Green tea | Catechin | General |
| Glycyrrhiza glabra | Licorice | Glabrol |
|
| Quercus rubra | Oak | Tannins Quercetin | |
| Allium cepa | Onion | Allicin | Bacteria and |
| Mahonia aquifolia | Oregon grape | Berberine |
|
| Thymus vulgaris | Thyme | Caffeic acid, Thymol, and Tannins | Viruses, bacteria, and fungi |
| Curcuma longa | Turmeric | Curcumin | Bacteria and protozoa |
Representation of various biomolecules derived from bacteria that have different biological activities/applications
| Type | Characteristics | Examples | Producer | Mode of action | References |
|---|---|---|---|---|---|
| Bacteriocin type I | Lantibiotics | Nisin Z and Q, Enterocin W |
| Pore formation in the membrane by permeabilisation | [ |
| Bacteriocin type II | Non Lantibiotics | Enterocin, |
| Pore formation in the membrane by permeabilisation | [ |
| Bacteriocin type III | Large peptides | Lysostaphin, Enterolysin A, |
| Disintegration of the cell-wall | [ |
| LPS | Peptides | Surfactin, |
| Antifungal, | [ |
| Other bioactive compounds | Vinaceuline |
| Antibacterial activity | [ | |
| Halocin |
| Alter membrane permeability | [ | ||
| Sulfolobicins |
| Exact mode of action is not known | [ | ||
| Lactones |
| Active against | [ | ||
| Jesterone | Pestalotiopsis jesteri | Active against | [ | ||
| Diastaphenazines |
| Antibacterial and antifungal activity | [ | ||
| Reuterin |
| Antimicrobial | [ | ||
| Mollemycin A 20 |
| Effective against Gram-positive and Gram-negative bacteria, compound shows antimalarial properties | [ | ||
| Avermectins |
| Onchocerciasis and lymphatic filariasis | [ | ||
| Cahuitamycins |
| Functional by inhibiting biofilm formation in Gram-negative | [ | ||
Figure 2Illustration of the mechanism of action of CRISPR/Cas in a bacterial cell. (a) Entry of genetic material of virus, phage, or plasmid into bacteria. (b) Short segments with genetic information of the invader inserts into CRISPR region. (c) Expression of crRNA in the bacterium. (d) Cleavage of the invading DNA by the formation of a cleavage complex consisting of foreign DNA, crRNA, and Cas9 protein.
Figure 3Role of antimicrobial peptides (AMPs): in general, (a), (b), and (c) Different types of AMPs act on the pathogens by penetrating the bacterial membrane through the porins and blocking various cellular and physiological processes of the cells, eventually leading to the death. (d) Inactivation of enzymes by peptide molecules. (e) Acts as ATPase inhibitor. (f) Induces cell death via interacting with intracellular DNAs and RNAs inducing DNA damage. (g) Cationic AMPs interact with organelles as in fungi such as mitochondria, eventually leading to fungal death. (h) Inhibition of the synthesis of protein and also cell wall. (i) Endocytosis.